Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Short term Debt: 2019

  • Avidity Biosciences' Short term Debt was N/A to $2.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was $2.8 million, marking a year-over-year change of. This contributed to the annual value of $2.8 million for FY2019, which is N/A change from last year.
  • Latest data reveals that Avidity Biosciences reported Short term Debt of $2.8 million as of Q4 2019.
  • Avidity Biosciences' 5-year Short term Debt high stood at $2.8 million for Q4 2019, and its period low was $2.8 million during Q4 2019.
  • Its 1-year average for Short term Debt is $2.8 million, with a median of $2.8 million in 2019.